Sri Vemulamanda

Sri Vemulamanda

Auto-generated profile, based on publicly available information

Sri Vemulamanda

Department of Otolaryngology/Head and Neck Surgery, UNC School of Medicine, Chapel Hill, North Carolina

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Figure 6. Survival Plot. Prognostic Value of NanoString NAC Classifier Measurements. In Figure 4, PFS was shown for (E) all patients and (F) de-escalation candidates in UNC and E1308 cohorts (non-smoker,

1 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Table 4. Association of NF-κB high and low groups with clinical parameters in combined UNC &E1308 cohorts (1) as pictured in Figure 4D-E. P-value assessed by χ2 test, except for age (assessed with t-test).

1 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Figure 5. NF-κB pathway mutations are found in cases with high NF-κB scores. A) NanoString NF-κB expression scores and NF-κB pathway mutational data from UNC cohort where both metrics were available. B) Non-linear least squares fit of mono-exponential function relating NanoString and RNAseq data. This fit was used to transpose the threshold defined by NanoString to the RNAseq data, where 3 more cases were available.

1 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Figure 2. UMAP dimensional reduction plot with malignancy probabilities from scMalignantFinder. Low probability predictions (<0.5) were imputed with to a value of 0.5 for visual clarity.

1 April 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Purpose: Patients with human papillomavirus–associated head and neck squamous cell carcinoma (HPV+ HNSCC) have relatively favorable outcomes, but standard treatments like radiation or chemoradiation frequently result in long-term toxic side effects. Appropriate patient selection has been a barrier to effectively de-escalate therapy for HPV+ HNSCC, and the absence of accurate biomarkers likely contributed to failure of recent promising de-escalation trials that rely on histologic tumor characteristics, history of tobacco use, or tumor response to chemotherapy; This deficiency underlines the need to develop and validate an assay to accurately detect two subtypes of HPV+ HNSCC—one with good prognosis and one with poor prognosis. Experimental Design: These two subtypes are distinguished by the activity of NF-κB in tumors. We first developed a DNA-based marker panel consisting of genes that when mutated would lead to NF-κB activation. Additionally, we developed a custom NanoString assay to determine the expression of NF-κB target genes. These assays were tested to determine their accuracy in detecting tumor subtype. Results: We demonstrate that the NF-κB gene signature score, as determined using the NanoString assay, could more accurately classify HPV+ HNSCC as compared with the DNA-based marker panel. Patients with a high NF-κB gene signature score demonstrated significantly increased overall survival, indicating more sensitivity to (chemo)radiation treatment. Conclusions: The NF-κB gene signature score can accurately predict response to standard (chemo)radiation in HPV+ HNSCC. This molecular biomarker holds promise for clinical use in identifying patients who are likely to benefit from treatment de-escalation strategies, potentially reducing long-term side effects without compromising therapeutic efficacy.

1 July 2026
Verified
Other
Open access
SVSri Vemulamanda
Sri Vemulamanda
AKAditi Kothari
Aditi Kothari
LCLoris De cecco
Loris De cecco
SKSulgi Kim
Sulgi Kim
AKAditi Kulkarni
Aditi Kulkarni
TSTravis P. Schrank
Travis P. Schrank
Supplemental Figure 1. Correlation plots for the: A) Metanalyisis-HPV267 (1) cohort; B) BD2-HPV286 (2) cohorts, comparing various summary metrics (mean, ssGSEA enrichment score and for the NF-κB RNA signature in microarray gene expression data. Values represent Pearson correlation coefficients. *** p-value of Pearson correlation <0.0005.